Review
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2013; 5(9): 186-194
Published online Sep 15, 2013. doi: 10.4251/wjgo.v5.i9.186
Primary hepatocellular carcinoma and metabolic syndrome: An update
Rubayat Rahman, Ghassan M Hammoud, Ashraf A Almashhrawi, Khulood T Ahmed, Jamal A Ibdah
Rubayat Rahman, Ghassan M Hammoud, Ashraf A Almashhrawi, Khulood T Ahmed, Jamal A Ibdah, Division of Gastroenterology and Hepatology, University of Missouri, Columbia, MO 65212, United States
Author contributions: Rahman R wrote and revised the manuscript; Hammoud GM, Almashhrawi AA and Ahmed KT were involved in reviewing the literature and collecting data; Ibdah JA conceived the topic, contributed to the writing, analyzed and edited the manuscript, and provided overall intellectual input into the design and execution of the manuscript.
Supported by Raymond E and Vaona H Peck Chair in Cancer Research
Correspondence to: Jamal A Ibdah, MD, PhD, Professor, Director, Division of Gastroenterology and Hepatology, University of Missouri-Columbia, 319 Jesse Hall, Columbia, MO 65212, United States. ibdahj@health.missouri.edu
Telephone: +1-573-8827349 Fax: +1-573-8844595
Received: May 26, 2013
Revised: August 14, 2013
Accepted: August 20, 2013
Published online: September 15, 2013
Processing time: 42 Days and 24 Hours
Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. The incidence of hepatocellular carcinoma has increased dramatically by 80% over the past two decades in the United States. Numerous basic science and clinical studies have documented a strong association between hepatocellular carcinoma and the metabolic syndrome. These studies have documented that, in most patients, non-alcoholic fatty liver disease is the hepatic manifestation of the metabolic syndrome, which may progress to hepatocellular carcinoma through the cirrhotic process. However, minority of patients with non-alcoholic fatty liver disease may progress to hepatocellular carcinoma without cirrhosis. This review summarizes the current literature of the link between hepatocellular carcinoma and metabolic syndrome with special emphasis on various components of the metabolic syndrome including risk of association with obesity, diabetes mellitus, hyperlipidemia, and hypertension. Current understanding of pathophysiology, clinical features, treatments, outcomes, and surveillance of hepatocellular carcinoma in the background of metabolic syndrome and non-alcoholic fatty liver disease is reviewed. With the current epidemic of metabolic syndrome, the number of patients with non-alcoholic fatty liver disease is increasing. Subsequently, it is expected that the incidence and prevalence of HCC will also increase. It is very important for the scientific community to shed more light on the pathogenesis of HCC with metabolic syndrome, both with and without cirrhosis. At the same time it is also important to quantify the risk of hepatocellular carcinoma associated with the metabolic syndrome in a prospective setting and develop surveillance recommendations for detection of hepatocellular carcinoma in patients with metabolic syndrome.

Keywords: Liver; Hepatocellular carcinoma; Metabolic syndrome; Non-alcoholic fatty liver disease; Obesity

Core tip: Hepatocellular carcinoma is a common malignancy with dismal outcome. The metabolic syndrome has been implicated for the recent increase in hepatocellular carcinoma. Numerous studies have shown a strong association between hepatocellular carcinoma and the metabolic syndrome. This review summarizes the current literature linking hepatocellular carcinoma and the metabolic syndrome.